logo
Billy Joel cancels all of his upcoming shows after revealing brain disorder diagnosis

Billy Joel cancels all of his upcoming shows after revealing brain disorder diagnosis

Billy Joel has canceled all upcoming concerts, revealing he has been diagnosed with a brain disorder that causes physical and mental issues.
Joel, 76, has normal pressure hydrocephalus, or NPH, according to a statement posted Friday on the piano man's social media. 'This condition has been exacerbated by recent concert performances, leading to problems with hearing, vision and balance,' the statement said.
'Under his doctor's instructions, Billy is undergoing specific physical therapy and has been advised to refrain from performing during this recovery period.'
Symptoms of NPH — in which cerebrospinal fluid accumulates in the ventricles of the brain but pressure doesn't increase — include difficulty walking, according to the Alzheimer's Assn. Sufferers walk with a wide stance and their bodies leaning forward, as if they were trying to maintain balance on a boat.
The association's website says that another symptom is cognitive decline, including slowed thinking, loss of interest in daily activities, forgetfulness, short-term memory loss and difficulty completing ordinary tasks. Later in the disease, bladder control can become an issue.
NPH is one of the few causes of dementia or cognitive decline that can be controlled or reversed with treatment, the association's website says. Surgical treatment usually involves placement of a shunt. The condition is often misdiagnosed as Alzheimer's or Parkinson's disease.
Danny Bonaduce of 'The Partridge Family,' radio and wrestling fame was diagnosed with NPH in 2023. The 65-year-old said in a 2024 interview that he initially thought he'd had a stroke, while doctors thought it was early-onset dementia or Alzheimer's. It took 'the better part of a year' for him to get a correct diagnosis, he said.
Bonaduce's memory loss appears to have been serious: He showed the interviewer a photo of himself in a wheelchair checking out the house where he and his wife now live. He said he has no memory of visiting the place multiple times before moving there.
Billy Joel's message Friday follows his mid-March announcement that he would postpone his upcoming tour to manage his health after surgery for an unspecified condition. At the time, the singer expected a full recovery after physical therapy.
Now, the statement said, Joel is 'thankful for the excellent care he is receiving and is fully committed to prioritizing his health' and 'looks forward to the day when he can once again take the stage.'
'I'm sincerely sorry to disappoint our audience, and thank you for understanding,' Joel said in Friday's statement.
In late February, the 'Just the Way You Are' singer fell after performing 'It's Still Rock and Roll to Me' in Connecticut. He quickly recovered; it's unclear whether that incident was a symptom of the disease or simply coincidental.
Times staff writer Alexandra Del Rosario contributed to this report.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains
28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains

Yahoo

time3 hours ago

  • Yahoo

28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains

Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes. The Nexon™ platform is now being used to improve the prediction of therapeutic efficacy and toxicity in humans, with several of the world's largest pharma companies already integrating Nexon™ into their drug development workflows. The Nexon™ platform also incorporates Organoid Intelligence (OI). The growing field of OI combines human brain organoids with brain-machine interfaces to model memory, learning, and cognition in vitro, offering novel functional cognitive biomarkers with the potential to reshape drug development in neurodegenerative disorders including Alzheimer's disease. Neurological drug development faces some of the highest failure rates in the pharmaceutical industry, due to poor translatability of animal models. Despite promising preclinical study results, many therapies ultimately fail in humans—contributing to a growing neurological health crisis and need for more predictive, human-relevant models. "We engineer human brains capable of elucidating the complexity of neurological processes and produce predictive data needed to change the trajectory of neurological drug development," said Alif Saleh, CEO of 28bio. "Industry and regulators are urgently asking for solutions to develop better neurological drugs faster and cheaper." About 28bio28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today's neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition. For more information, visit View original content to download multimedia: SOURCE 28bio Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Simple tool could detect Parkinson's disease early — it was 96% accurate in experiments
Simple tool could detect Parkinson's disease early — it was 96% accurate in experiments

New York Post

time10 hours ago

  • New York Post

Simple tool could detect Parkinson's disease early — it was 96% accurate in experiments

This pen truly is mightier than the sword. A team of researchers at UCLA has developed a high-tech diagnostic pen that can detect signs of Parkinson's disease with over 96% accuracy, offering a low-cost way to identify the neurodegenerative disorder far earlier than now. A pilot study in the journal Nature Chemical Engineering unveiled the device, which looks much like a regular pen. 3 A patient with PD using the diagnostic pen for a writing task. Nature Chemical Engineering It's able pick up on subtle motor dysfunctions before they're visible to the naked eye, all by analyzing how people write. So, how does this futuristic fountain pen work? The tip is made of a flexible silicone material infused with magnetic particles, and it writes using a special ferrofluid ink that contains nanomagnets. As someone writes, pressure from the hand deforms the tip, causing changes in magnetic fields that produce electrical signals — like a Morse code of motor function. Those signals are then analyzed to detect the difference between healthy and Parkinson's-affected motor patterns. In tests with 16 participants — including 3 with Parkinson's — the system nailed the diagnosis with 96.22% accuracy. Even more impressive? The pen worked whether people wrote on paper or in the air, meaning it doesn't even require a surface. 3 Nature Chemical Engineering Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. This diagnostic pen is portable, inexpensive and doesn't rely on a neurologist to interpret results, making it a promising option for remote screenings, home use or even telehealth checkups. 'Our development of the diagnostic pen represents a low-cost, widely disseminable and reliable technology with the potential to improve PD diagnostics across large populations and resource-limited areas,' the researchers wrote. With further validation in a larger population, the device could be used not just for early diagnosis, but for ongoing symptom tracking and personalized treatment monitoring. 3 Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. highwaystarz – This is just the latest innovation aimed at tackling Parkinson's disease, which affects more than 10 million people worldwide and has no known cure. A recent study found that psilocybin — the psychedelic compound that gave 'magic mushrooms' their trippy reputation in the 1960s — showed serious promise for improving mood and motor function in people with Parkinson's disease. Tavapadon — a new drug that mimics dopamine by targeting certain receptors — has also shown promise in clinical trials by reducing motor fluctuations and maintaining symptom control with fewer side effects than traditional therapies. Produodopa — a continuous infusion therapy first administered in the UK — was approved by the US Food and Drug Administration last fall. Innovative approaches targeting the psychological aspects of the disease have been successful as well — with tandem cycling proving to be especially popular. Some New Yorkers even find relief by playing pingpong.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store